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Summary 11 
Multi-purpose prevention technologies (MPTs) that aim to simultaneously prevent 12 
unintended pregnancy, human immunodeficiency virus type 1 (HIV-1) infection and 13 
other sexually transmitted infections (STIs) are among the most innovative and complex 14 
products currently in development within women’s sexual and reproductive healthcare. In 15 
this review article, MPTs are placed within the wider context of combination products, 16 
combination drug products and multi-indication products. The current MPT product 17 
landscape is mapped and assessed with reference to existing products for the 18 
corresponding single indications, before identifying the gaps in the current MPT product 19 
pipeline and highlighting priority products and challenges moving forward.  20 
Introduction 21 
Since 2010, following the first encouraging data to emerge from clinical testing of an 22 
antiretroviral-based HIV microbicide candidate1, there has been extensive talk, 23 
consideration and early stage development around next generation products, termed 24 
‘multipurpose prevention technologies’ (MPTs), that aim to combine HIV prevention 25 
with prevention of unintended pregnancy and/or prevention/treatment of other sexually 26 
transmitted infections (STIs) and reproductive tract infections (RTIs). In addition to the 27 
significant number of agenda-setting and commentary/review articles published on 28 
MPTs,2-10 there has also been a limited number of original research articles describing 29 
new MPT concepts.11-15 MPTs are not a new product class, despite the new (and 30 
somewhat confusing) name. Male condoms, which offer effective barrier protection 31 
against pregnancy, HIV and other STIs, have been used for more than 400 years, and 32 
their female counterparts have been available since the 1980s. However, despite their 33 
effectiveness, condoms are often not used consistently and correctly and have clear 34 
limitations for women. Therefore, there is an urgent need for new and innovative MPT 35 
products that offer women in particular greater choice and improved acceptability in 36 
controlling their sexual and reproductive health. 37 
 38 
With recent interest focused almost exclusively on microbicidal-based (and, more 39 
specifically, antiretroviral-based) strategies for prevention of sexual transmission of HIV, 40 
newer MPT approaches have inevitably included at least one active pharmaceutical 41 
ingredient (API), resulting in either a ‘combination product’ (CP) or a ‘combination drug 42 
product’ (CDP), to use more conventional pharmaceutical regulatory terminology (Table 43 
1, Figure 1). For example, the microbicide-releasing diaphragm device recently reported 44 
is considered a ‘combination product’ (Table 1, Figure 2), comprising a medical device (a 45 
cervical barrier diaphragm) coupled with an additional drug delivery function (controlled 46 
release of an antiretroviral microbicide).13 A vaginal ring device that provided 47 
simultaneous sustained/controlled release of an antiretroviral, a contraceptive 48 
progestogen and/or an anti-HSV drug would formally be classified as ‘combination drug 49 
products’ (Table 1, Figure 1, Figure 2).16,17 Regulatory definitions of a ‘medical device’ 50 
and a ‘drug delivery device’, for which there is often considerable confusion, are also 51 
provided in Table 1.  52 
 53 
Combination drug products: the wider context for MPTs 54 
Many of the MPT strategies currently being pursued rely solely on simultaneous delivery 55 
of muliple APIs, and are therefore formally classified as CDPs. For this reason, it is 56 
worth considering CDPs in more detail to help contextualise MPTs. CDPs (also known as 57 
‘fixed-dose combinations’; Table 1, Figure 1, Figure 2) have become increasingly 58 
important in the public health arena. CDPs comprise a particular combination of actives, 59 
in a fixed ratio of doses, that is both safe and effective and where each API contributes to 60 
the overall therapeutic effect. For patients, these combination products often lead to 61 
simplified therapy, improved clinical effectiveness, reduced incidence of adverse side 62 
effect and increased adherence.18-20 For pharmaceutical companies, CDPs also offer 63 
excellent opportunities for life cycle management of marketed drug products. Currently 64 
marketed CDPs are mapped in Figure 1 according to the number of APIs in the product 65 
and the number of clinical conditions that the product is intended to treat. Unlike the vast 66 
majority of drug products that contain a single active and treat a single disease, marketed 67 
CDPs comprise two, three and even four actives for treatment of a single disease, most 68 
commonly HIV/AIDS, asthma, malaria, contraception, high blood pressure and 69 
tuberculosis (Figure 1). Examples of CDPs that are used in the treatment of two distinct 70 
(but clinically related) diseases include Caduet®/Envacar® (containing atorvastatin and 71 
amlodipine; used in the treatment of high cholesterol and high blood pressure, 72 
respectively) and Juvisync™ (containing sitagliptin and simvastatin; used in the 73 
treatment of diabetes and high cholesterol, respectively) (Figure 1). Not surprisingly, the 74 
complexities associated with preclinical and clinical development of multi-indication 75 
products, including CDPs and MPTs, are signficantly greater than those for single API 76 
products.  77 
 78 
Multipurpose prevention technologies (MPTs) 79 
MPTs are effectively a sub-category of CPs and CDPs, specifically focused on prevention 80 
of a triad of specific (and inter-related) clinical conditions within women’s sexual and 81 
reproductive health, namely pregnancy, HIV infection and/or other STIs. As such, MPTs 82 
are multi-indication products (Figure 1), either comprising (i) multiple active agents, 83 
individually effective for a different indication, (ii) a single active agent effective for 84 
multiple indications (e.g. a single active drug with both microbicidal and contraceptive 85 
properties), or (iii) one or more active agents incorporated into a medical device (e.g. a 86 
microbicide-releasing condom or diaphragm). Figure 3 provides an overview of the 87 
formulation/dosage form options being used or actively developed for 88 
prevention/treatment of the individual clinical indications and the various combinations 89 
of indications that define MPTs. 90 
It is worth making several comments based on Figure 3. First, the mature contraceptive 91 
market offers the greatest choice of formulation options, with thirteen distinct product 92 
types administered across a very diverse range of delivery routes (i.e. oral, vaginal, 93 
subdermal, subcutaneous, cervical and transdermal). This diversity is rather unique, 94 
particularly given the rather limited choice of APIs currently available for contraception.  95 
The main factors contributing to the diversity of dosage forms and delivery routes used 96 
for hormonal contraceptives include: (i) contraceptive drugs may be delivered locally or 97 
systemically, although most are administered systemically, (ii) the relatively high 98 
therapeutic potency of hormonal contraceptive agents, at least compared with currently 99 
available antiretrovirals and anti-STI agents, and (iii) consequently, the need for only 100 
very low doses for clinical efficacy. It is likely that the next generation of MPT products 101 
will be based around these existing contraceptive technologies rather than a completely 102 
new product concept. 103 
Second, seven MPT strategies have been identified within the intersection areas of the 104 
Venn diagram in Figure 3 (products identified by the following codes: 1DJ, 6G, 6+9D, 105 
9D, 11A, 11G and 11AG). Most of these MPT products are in pre-clinical development 106 
(condoms being the exception) and all are based upon existing contraceptive 107 
technologies, most notably vaginal gels, vaginal ring and cervical diaphragms. 108 
Interestingly, this observation largely reflects current HIV microbicide development 109 
priorities and MPT product preference research, in which women rate favourably 110 
products that are easy to use and/or increase adherence.21 Since product adherence will be 111 
critical for the clinical effectiveness of MPTs (as it is for HIV microbicides), sustained 112 
release products, such as vaginal rings, subcutaneous injectables and subdermal implants, 113 
have been identified using target product profile (TPP) methodology as a development 114 
priority. 115 
Third, current MPT development work is focused primarily on HIV+contraception and 116 
HIV+HSV strategies (Figure 2), the former reflecting women’s health priorities in 117 
Africa5 where HIV is most prevalent, and the latter the fact that vaginally-administered 118 
tenofovir is inherently active against both HIV and HSV.11,14,22  119 
 120 
Where are the gaps in the MPT product pipeline? 121 
It is not surprising that HIV prevention is a major component of most current MPT 122 
strategies, since MPT research has stemmed primarily from within the HIV microbicide 123 
field. Based on consideration of Figure 3 and the associated scientific literature, certain 124 
gaps and deficiencies in the MPT product landscape can be readily identified. 125 
(i) There is an over-reliance on reverse transcriptase inhibitors (RTIs) for topical (vaginal 126 
and rectal) HIV prevention. This is particularly true of tenofovir and to a lesser extent 127 
dapivirine, both of which are lead candidate microbicides currently in late stage clinical 128 
testing. Anti-HIV compounds other than RTIs are slowly beginning to emerge as 129 
potential microbicides. These include small-molecule CCR5 entry inhibitors such as 130 
maraviroc and CMPD167,23-26 integrase inhibitors,27 protease inhibitors28 and various 131 
peptides/proteins.29,30 However, very few of these HIV inhibitor molecules have 132 
progressed to early stage clinical testing as microbicides, despite the fact that many are 133 
already marketed for HIV treatment. 134 
(ii) There is presently a distinct lack of interest/commitment in the development of non-135 
antiretroviral HIV prevention methods, although this has not always been the case. 136 
Previously, several non-antiretroviral microbicide candidates, including nonoxynol-9, 137 
cellulose sulphate, BufferGel, Carraguard and PRO 2000, were evaluated in late stage 138 
effectiveness trials, although none demonstrated protection.31 Vivagel, a second 139 
generation non-antiretroviral microbicide comprising a dendrimer-based gel product, has 140 
shown a broad spectrum of activity against HIV and HSV-2,32,33 although it is mostly 141 
being evaluated in ongoing clincial studies for the treatment of bacterial vaginosis. The 142 
general lack of specificity and potency of these non-antiretroviral microbicides is mostly 143 
attributed to the fact that their mechanisms of antiviral activity are confined to disrupting 144 
the virus or preventing its attachment to cells in the vaginal lumen rather than the 145 
intracellular activity afforded by antiretrovirals. Also, many of these non-antiretroviral 146 
microbicides were developed as coitally dependent, on-demand vaginal gel formulations, 147 
which, although being considered for MPTs, are probably not as high a priority as 148 
sustained release products. 149 
(iii) Given ongoing concerns over the short and long term side effects associated with 150 
hormonal contraceptives (such as irregular bleeding, weight gain, nausea or lower libido, 151 
and slightly increased risk for certain cancers), the lack of innovation around non-152 
hormonal contraceptive methods that might be leveraged by new MPT products is rather 153 
surprising. Barrier methods (exemplified by condoms, diaphragms and cervical caps) and 154 
the Paragard® intrauterine device, are the most common non-hormonal devices used for 155 
contraception. Of these products, only the diaphragm is presently being considered as a 156 
potential MPT, either used in combination with an antiretroviral gel34 or through direct 157 
incorporation (and subsequent slow release) of an antiretroviral drug into the polymeric 158 
spring core component of diaphragm device itself.13 Investment in new contraceptive 159 
technologies, and particularly non-hormonal methods, is needed to achieve consistent and 160 
correct contraceptive use, to lower unintended pregnancy rates, and to widen 161 
contraceptive choice for women.  162 
(iv) There appears to be no current activity in the development of non-HIV MPT methods 163 
(Figure 3), despite the fact that strategies that focus on preventing pregnancy and other 164 
STIs are deemed priority indications in a number of countries, including India, China and 165 
potentially Europe and the USA.21 Potent new drugs that specifically target other STIs are 166 
generally lacking, and identifying pathogen-specific actives for both bacterial and viral 167 
STIs is certainly a key priority in future MPT development. 168 
(v) MPT product concepts comprising a vaccine component to target any of the three 169 
clinical indications that define MPTs are much further down the developmental pipeline 170 
compared with non-biologic strategies.10 Although HIV and contraceptive vaccines are in 171 
development, only an HPV vaccine is currently available (Figure 3). In general, biologic-172 
based MPT product concepts remain largely unexplored. A vaccine and microbicide 173 
combination for preventing HIV-1 sexual transmission has been reported recently, albeit 174 
the components are administered separately via the intramuscular and intravaginal routes, 175 
respectively.35 Potential MPT product concepts offering a vaccine component include a 176 
single-dose depot injection comprising a contraceptive hormone (like Depo Provera®) 177 
combined with an HIV or STI antigen, or a vaginal ring device delivering a vaccine 178 
candidate (either HIV or STI) and one or more ARV-based HIV microbicides. Vaginal 179 
ring devices suitable for formulation and sustained release of biologics have been 180 
reported.15,36 181 
 182 
(vi) Sustained/controlled release progestogen-only products in the form of subcutaneous 183 
injectables (e.g. Depo Provera) and subdermal implants (e.g. Nexplanon/Implanon) are 184 
already marketed for long-term contraception. In fact, Depo Provera is the most common 185 
form of contraception in Africa. It is conceivable that MPT products could be developed 186 
based around existing injectable and implantable progestogen formulations. However, a 187 
major challenge would be achieving sufficient loading and release of the antiretroviral 188 
and/or anti-STI drug(s) to prevent sexual transmission of the associated 189 
microorganism(s). To date, this product concept has not been widely considered.   190 
 191 
What are the MPT product priorities moving forward? 192 
A key consideration for future MPT products will be user adherence to the prescribed 193 
regimen, a particularly pertinent issue for on-demand products. The importance of user 194 
adherence is well understood and documented within the contraceptive field, where the 195 
differences between actual-use and perfect-use failure rates are highly dependent on 196 
whether the products are user-dependent (e.g. oral pill, diaphragm, vaginal ring) or non-197 
user dependent (e.g. intrauterine device, injectable, implant, and sterilisation).37,38 198 
Growing concern over (lack of) adherence to experimental microbicide products and 199 
placebos in clinical studies, particularly with vaginally administered gel products,1,39,40 200 
has led to prioritisation of sustained release over on-demand methods for MPTs. 201 
Sustained drug release vaginal rings are already marketed for contraception (Nuvaring® 202 
and Progering®), estrogen replacement therapy (Estring® and Femring®) and hormone 203 
supplementation during in vitro fertilisation (Fertiring®). Rings releasing small molecule 204 
antiretrovirals are also at the forefront of current HIV microbicide efforts.41-43. A vaginal 205 
ring comprising 25 mg of the non-nucleoside reverse transcriptase inhibitor dapivirine 206 
(also known as TMC120) dispersed within a silicone elastomer matrix44-46 is presently 207 
being tested in two Phase III studies (MTN-020 and IPM027) in Africa. Although high 208 
levels of acceptability and user adherence have been reported for non-microbicide vaginal 209 
rings 47-57, it is not yet clear if microbicide-releasing rings will offer improved adherence. 210 
The ability to combine and/or compartmentalise multiple drugs within a single ring 211 
device bodes well for developing a practical ring-based MPT strategy.15,23,26,41,58  212 
 213 
The challenges moving forward 214 
Despite the obvious urgency for development of new MPT products for use in both 215 
developed and developing countries, the only options currently available for simultaneous 216 
protection against unintended pregnancy, HIV and/or other STIs remain male and female 217 
condoms. None of the MPTs currently in development have yet progressed beyond 218 
preclinical testing, although an investigational new drug (IND) application has recently 219 
been submitted for the tenofovir/levonorgestrel vaginal ring. When they do eventually 220 
make it to clinic, many complex hurdles and challenges will likely prevent a quick route 221 
to market. For example, the same issues that may challenge antiretroviral-based HIV 222 
prevention around the potential for development of resistant virus will also apply to MPT 223 
products containing antiretrovirals. This is likely to fuel demand for sustained release 224 
products that promote user adherence. Also, given the complexity of multi-indication 225 
combination products having constituent parts corresponding to drug products, medical 226 
devices and biologics, MPTs will invariably involve unique and challenging regulatory 227 
considerations. Regulatory challenges, considerations, and decisions will be product-228 
specific as well as indication-specific. In both the EU and the US, a single regulatory 229 
center will have primary jurisdiction for the MPT product, and assignment is based on the 230 
product’s primary mode of action (although quite how the primary mode of action will be 231 
defined is still unclear for many product concepts). Other major challenges for MPTs 232 
include the design and assessment of results from clinical studies and appropriately 233 
scaled manufacturing solutions for what are likely to be relatively complex and possibly 234 
expensive devices. 235 
 236 
Conclusions 237 
Increased awareness and interest in new MPTs have largely been stimulated by recent 238 
progress in the HIV microbicide field with the continued clinical development of the 239 
tenofovir vaginal gel and the dapivirine vaginal ring. Based on the current clinical 240 
schedules, and depending upon study outcomes, successful approval of these products is 241 
unlikely before 2015. Meantime, in preparation for success and in order to ensure rapid 242 
follow-through, it is imperative that new MPT concepts are considered, funded, 243 
developed and evaluated now. Perhaps more than any other drug/combination product 244 
type to date, MPTs will require diverse and extensive collaborative efforts across multiple 245 
disciplines in order to achieve the laudable goal of creating innovative and converged 246 
technologies that simulataneously address the most important issues in women’s sexual 247 
and reproductive health today.   248 
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 Figure 1. Mapping of number of active pharmaceutical ingredients per product 
versus number of clinical indications per product for ‘combination products’ and 
‘combination drug products’ (including MPTs) (see Table 1 for definitions). MPTs 
fall within the product categories targeting two or more clinical indications, 
irrespective of the number of pharmaceutical ingredients in the product. Italicised 
text indicates representative marketed products or product classes. Non-italicised 
text indicates products in development. Underlined text represents MPT 
products. 
  
  
Figure 2. Classification and regulatory framework for drug products, biologic 
products, medical devices and their combination products (depicted in grey). 
MPTs may be placed within several of these sub-categories, including medical 
devices, combination products, and combination drug products (CDP). A 
combination biological product (not shown) targeted at two or more clinical 
indications (pregnancy, HIV and/or other STIs) would also classify as a MPT 
product. The product types indicated in the diagram are examples representative 
of the classification.   
 
  
Figure 3. Marketed and development product landscape for prevention/treatment 
of HIV, pregnancy, and other sexually transmitted diseases. All of the products 
captured within the HIV circle contain one or more antiretroviral compounds that 
act against HIV. Intersection areas (depicted in grey) represent MPT products. * 
HPV can infect areas that are not covered by a condom, and therefore condoms 
may not fully protect against HPV (http://www.cdc.gov/std/hpv/stdfact-hpv.htm) 
Table 1. Definition of key terms 
 
Term Definition 
‘combination drug’, 
‘combination drug 
product’ or ‘fixed dose 
combination’ 
a single dosage form comprising two or more active pharmaceutical 
ingredients (APIs); may target single or multiple (often related) 
disease states; in tablet or capsule form, combination drugs are 
referred to as ‘polypill’ or ‘combopill’ 
‘combination product’ a product comprised of any combination of a drug and a device; a 
biological product and a device; a drug and a biological product; or 
a drug, device, and a biological product 
‘combination therapy’, 
‘polytherapy’ or 
‘polypharmacy’ 
use of more than one medication or therapy; most commonly used 
to treat a single disease; may involve administration of separate 
drug products or combination drug products; conditions treated with 
combination therapy include tuberculosis, leprosy, cancer, malaria, 
and HIV/AIDS; ‘polypharmacy’ is often defined as the use of five or 
more regular medications (more common in older patients). 
‘drug delivery device’ any device that provides delivery of one of more drug substances  
‘medical device’ "any instrument, apparatus, appliance, software, material or other 
article, whether used alone or in combination, including the software 
intended by its manufacturer to be used specifically for diagnostic 
and/or therapeutic purposes and necessary for its proper 
application, intended by the manufacturer to be used for human 
beings for the purpose of: diagnosis, prevention, monitoring, 
treatment or alleviation of disease; diagnosis, monitoring, treatment, 
alleviation of or compensation for an injury or handicap; 
investigation, replacement or modification of the anatomy or of a 
physiological process; control of conception; and which does not 
achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which 
may be assisted in its function by such means;" (Medical Devices 
Directive 93/42/EEC (MDD)) 
‘medicinal product’ “any substance or combination of substances presented as having 
properties for treating or preventing disease in human beings; [or] 
any substance or combination of substances which may be used in 
or administered to human beings either with a view to restoring, 
correcting or modifying physiological functions by exerting a 
pharmacological, immunological or metabolic action, or to making a 
medical diagnosis.” (European Union Directive 2004/27/EC) 
‘monotherapy’ use of a single medication for treatment of a single disease 
‘multi-purpose prevention 
technology’ 
the term is exclusively used to describe technologies, preferably 
single-product technologies, that simultaneously address at least 
two of the following clinical needs: (i) prevention of unintended 
pregnancy, (ii) prevention of HIV, (iii) prevention or treatment of 
other sexually transmitted or reproductive tract infections 
 
